Header Image

Glaucoma Disease

A leading cause of blindness in the world, it is a progressive optic neuropathy often associated with increased intraocular pressure and characterized by progressive death of retinal ganglion cells (RGCs).1 The European Glaucoma Society recognizes neuroprotection as an adjuvant treatment option in glaucoma2 and there is evidence that coenzyme Q1O has a potential retinal neuroprotective action.1,4-6 Topical CoQ1O has proved to be an effective therapy preventing RGC apoptosis and losing glaucoma-related models.5* This is due to its anti-apoptotic, antioxidant and bioenergetic properties.3,7

1. Nucci C, Tartaglione R, Cerulli A, Mancino R, Spanò A, Cavaliere F, et al. Int Rev Neurobiol 2007; 82: 397-406.
2. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th Edition. 2014.
3. Qu J et al. Invest Ophthalmol Vis Sci 2009; 50: 1814-1818.
4. Guo L, Cordeiro MF. Prog Brain Res 2008; 173: 437-450.
5. Davis BM, Tian K, Pahlitzsch M, Brenton J, Ravindran N, Butt G, et al. Mitochondrion 2017; 36: 114-123.
6. Noh YH, Kim KY, Shim MS, Choi SH, Choi S, Ellisman MH, et al. Cell Death Dis 2013; 4: e820.
7. Fato R et al. Acta Ophthalmol 2010; 88(4): e150- 1.


Complementary treatment to antihypertensive glaucoma therapy

Product Image